作者: Sibille Everhard , Gentian Kaloshi , Emmanuelle Criniere , Alexandra Benouaich‐Amiel , Julie Lejeune
DOI: 10.1002/ANA.21044
关键词: Temozolomide 、 Neoadjuvant therapy 、 Survival rate 、 Glioma 、 Internal medicine 、 Biology 、 Temozolomida 、 Methylation 、 Chemotherapy 、 Oncology 、 Mgmt methylation 、 Immunology
摘要: The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide. Methylated MGMTP detected 63 (92.6 %) patients and a favorable predictor progression-free survival as compared with unmethylated tumors (p < 0.0001). Assessment could help identifying more likely to respond chemotherapy or benefit from MGMT depletion strategies.